The LDI is among Canada’s leading health research institutes. Through their fundamental and clinical investigations, our scientists and clinicians make significant discoveries, lead important provincial and national research programs, and train emerging scientists who, themselves, are recognized for the excellence of their work, contributing to the health and well-being of patients in Quebec, Canada, and around the world.
At the Lady Davis Institute for Medical Research (LDI), equity, diversity and inclusion are at the heart of who we are. We are committed to provide people working in the LDI community with exemplary, highest quality of work and learning environments that are healthy, equitable and inclusive, free from all forms of discrimination and where every person can feel welcomed and recognized, but also involved and contributing to the present and the future of the LDI.
Discover our 200+ regular and associated investigators and their research, as well as the many services we provide across the spectrum of the research process.
We offer the 250+ graduate and postdoctoral students who come to the LDI each year an open, collaborative, and multidisciplinary training environment that fosters excellence.
The close collaboration between researchers, clinicians, and patients is at the basis of the most successful research programs and clinical trials at the LDI.
At the Lady Davis Institute for Medical Research (LDI), equity, diversity and inclusion are at the heart of who we are. We are committed to provide people working in the LDI community with exemplary, highest quality of work and learning environments that are healthy, equitable and inclusive, free from all forms of discrimination and where every person can feel welcomed and recognized, but also involved and contributing to the present and the future of the LDI.
Aspirin after rivaroxaban and aspirin alone appear to be similar in their capacity to reduce the risk of venous thromboembolism after total hip or knee arthroplasty. Research findings from the EPCAT III trial are summarized in a new Quick Take video. https://nej.md/4iJ8cC7
New in the November 12, 2026, issue of NEJM:
Rivaroxaban vs. Aspirin Alone after Arthroplasty (EPCAT III trial) https://nej.md/44j0Bne
Prevention of VTE after Total Hip or Knee Replacement (PEPPER trial) https://nej.md/4iIxVL0
Prasugrel vs. Ticagrelor in Acute Coronary
Congratulations to @McGillMed researchers who received funding through Cancer Research Society (@SRC_CRS) Operating Grants! 👏
Read more ➡️
La communauté de l'HGJ/ILD est attristée par le décès, le 10 novembre 2026, du Dr Samuel O. Freedman, O.C., C.Q., FRSC, qui a été directeur de @LDI_ILD de 1991 à 2000. Nos pensées vont aux proches et aux collègues du Dr Freedman en cette période de deuil.
https://bit.ly/4iOaU9o